Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
about
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryPurine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.Inpatient Antineoplastic Medication Administration And Associated Drug Costs: Institution of a Hospital Policy Limiting Inpatient Administration.Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant diseaseTargeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells.BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHDPrognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.Bendamustine reactivates latent Epstein-Barr virus.Bendamustine: role and evidence in lymphoma therapy, an overview.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?Temsirolimus acts as additive with bendamustine in aggressive lymphoma.A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphomaAnti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma.Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.[Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma.Japanese apricot extract (MK615) potentiates bendamustine-induced apoptosis via impairment of the DNA damage response in lymphoma cells.Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine.Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.Efficacy of bendamustine on thrombocytopenia and hemolytic anemia secondary to CD5-positive B-cell lymphoma with massive splenomegaly in a patient with rheumatoid arthritis.Favorable response of relapsed/refractory gray-zone lymphoma to brentuximab vedotin.Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding studyBendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
P2860
Q28088365-349904F2-C745-45E0-AA35-D44DC78D8128Q28540830-3334A6E7-E26F-4430-982A-DF0BB31828F5Q30235296-27F811AA-DB66-4735-9071-FE758C5C2F44Q33409872-3D5EAC98-77EC-4A8E-B5C9-0C101647B32CQ33410756-AA6F2196-FD18-4E59-B4FA-AE91A6574A0BQ33416550-26F945E6-CBB7-4113-8DF6-FDB38A6BC7C7Q33429865-18EC92D0-6F5C-48D3-A8F0-D6A7A89BF4FFQ33440251-E3602738-7724-47C9-B82F-FADBAA386F52Q33714214-E3600FD8-5799-4951-9615-32E04A6FE6C7Q33911781-ABC6FD01-D1AF-4A03-8FED-4035DCB0934BQ34507114-F86C7C4F-1C5A-400F-98CA-536A089F45BAQ34660110-837DEB2B-80D3-437E-8014-34989A3C1D71Q35439403-E981A22D-254E-4957-862F-336B9EFF10F3Q37094781-FDAD6E2B-95D6-4F4C-94F7-2B87738919DAQ38158084-3300DF2E-6018-4C46-B19C-D52C7202D53FQ38548134-91F70A29-444E-4053-A496-1C030F627972Q38642648-5CD13F7A-45AE-418C-BC37-70FDC3623F5CQ38700745-6CB502F9-D4FB-4664-A356-0BE12D703ADEQ38812293-C5FAC3C8-F5A3-4651-B2FA-0F8756A0A43EQ38838789-CFFA88C0-04B5-4730-B750-B662AABAB1C8Q38862949-F0861D83-6E63-4406-993C-5E0A3F473FAFQ38947107-0398EDF0-16A3-4CF9-B9FD-5428EDF3841EQ39031363-D704EEB4-CB48-4166-B26C-A92C4EF26D0CQ39839569-4B4B4E67-D630-43C1-B6CF-D140A8ECA9D3Q39938060-52A19908-AEAA-4735-9241-C311A5309764Q40080582-63B6F36E-EFD2-4919-8C24-A301F51137FBQ40449915-9440DF25-F3A2-4E10-A215-49DC0D5DFDA7Q40533017-3A8C24F7-22E8-445A-8C36-EED3C45CDE86Q40978733-82D35EF2-F03A-4624-A4BF-865E0A3E3BDFQ41362824-40FBB965-5477-408E-8298-F2D0FA3E8BDAQ43185836-3BF9FD4A-D171-402D-9A98-D84C59EFEB00Q47122954-145AED83-0368-4EE4-A693-58BC91F98731Q48190434-C2B3760A-680F-43C5-9856-CB91382DC165Q52893159-33D6058B-1D8B-4870-9927-6076C1F9AE93Q52895479-A53686D6-2ADA-43EA-9060-6F6187EC6A81Q53758719-09F610BD-D25C-4564-9A42-78C0412064E9Q54205796-F4B9091C-061C-4259-BCD0-9EE40D8F86E9Q54214982-5BD280EB-77F0-48C9-9F4A-615761DADF5BQ57162415-1D421321-37B4-4716-BC3B-50EF0B649C2AQ57494289-710CD88B-4945-46A6-A9AF-5D5134CC3C84
P2860
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Multicenter phase II study of ...... diffuse large B-cell lymphoma.
@ast
Multicenter phase II study of ...... diffuse large B-cell lymphoma.
@en
type
label
Multicenter phase II study of ...... diffuse large B-cell lymphoma.
@ast
Multicenter phase II study of ...... diffuse large B-cell lymphoma.
@en
prefLabel
Multicenter phase II study of ...... diffuse large B-cell lymphoma.
@ast
Multicenter phase II study of ...... diffuse large B-cell lymphoma.
@en
P2093
P356
P1476
Multicenter phase II study of ...... diffuse large B-cell lymphoma.
@en
P2093
Cheolwon Suh
Hyeon Seok Eom
Ken Ohmachi
Kensei Tobinai
Kiyoshi Ando
Michinori Ogura
Mitsuaki Tatsumi
Naoki Takahashi
Naokuni Uike
Naoto Takahashi
P304
P356
10.1200/JCO.2012.46.5203
P407
P577
2013-05-06T00:00:00Z